← Back to Search

Enzyme Replacement Therapy

Treatment for Hunter Syndrome

N/A
Waitlist Available
Research Sponsored by Takeda
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Summary

As the HGT-HIT-046 (NCT01506141) and SHP609-302 (NCT02412787) studies will be closed, this post-trial access (PTA) program provides TAK-609 to participants in these studies for whom the benefit:risk ratio of continued treatment with idursulfase-IT remains positive.

Eligible Conditions
  • Hunter Syndrome

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Find a Location

Who is running the clinical trial?

TakedaLead Sponsor
1,227 Previous Clinical Trials
4,222,505 Total Patients Enrolled
4 Trials studying Hunter Syndrome
38 Patients Enrolled for Hunter Syndrome
Study DirectorStudy DirectorTakeda
1,252 Previous Clinical Trials
504,379 Total Patients Enrolled
14 Trials studying Hunter Syndrome
1,791 Patients Enrolled for Hunter Syndrome
~233 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top